Aktie NPTX NEUROPATHIX, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Neuropathix, Inc.

Aktien

NPTX

US64132Q1094

NPTX

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
NEUROPATHIX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
Neuropathix : OTC Certification - Neuropathix, Inc. - FYE 2021
Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
NEUROPATHIX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)
Neuropathix, Inc. Auditor Raises 'Going Concern' Doubt
NEUROPATHIX, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
Neuropathix, Inc. announced that it has received $0.15 million in funding
NEUROPATHIX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Neuropathix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
NEUROPATHIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Neuropathix, Inc. Appoints Michael Ropacki to its Scientific Advisory Board
NEUROPATHIX : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Neuropathix, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
Neuropathix : Neuropathix, Inc.
NEUROPATHIX : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
Neuropathix, Inc. Announces Publication of Validated Preclinical Studies on KLS-13019 in the British Journal of Pharmacology
NEUROPATHIX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)
Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. NPTX Aktie
  4. Nachrichten Neuropathix, Inc.
  5. Andere Sprachen